The Turkish pharmaceutical industry is aiming to undergo a fundamental shift over the coming years in an attempt to move from being largely a generics producer to a global centre for the production of original medicines. Its government wants Turkey to be one of the world’s top 10 economies in health services by 2023 – the centenary of the establishment of the Turkish Republic – and to become the Eurasian production base for medium- and high-level technology products.
Ankara’s aims were outlined in a report titled: ‘Turkey’s Pharmaceutical Sector: Vision 2023’, published in 2012 by Turkey’s Association of Research-Based Pharmaceutical Companies (AiFD), which put forward a strategy of how these aims can be achieved.
The report declared: ‘Turkey’s pharmaceutical industry has enough infrastructure and potential to…become a global player.’ It observed that, located as a bridge between Europe and Asia, Turkey is well situated geographically ‘with a high possibility....of exports to markets such as the Middle East and Eastern Europe’. It added that the Turkish industry has a ‘strong education capacity in fundamental sciences, medicine and pharmaceutical departments’, with the number of specialist physicians increasing from 18,000 to 31,000 from 2002 to 2012, and that Turkey has ‘competency in diagnosis and treatment’, with healthcare tourism developing strongly over recent years.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.